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The ‘Lebombo cluster leaf’ Terminalia phanerophlebia (Combretaceae) is used in traditional medicine in South Africa for a host of ailments, including
aches and pain, wounds and infections, gynaecological conditions, inﬂammation, mental illness such as epilepsy, and sexually-transmitted diseases. Based
on the anti-inﬂammatory activity (92.4% inhibition of the cyclooxygenase enzyme COX-2) initially observed for a crude extract, stems of
T. phanerophlebiawere here examined for the underlying phytochemical principles. Three cholestane triterpenoidsβ-sitosterol,β-sitostenone and stigmast-
4-ene-3,6-dione were isolated from the ethanol extract by silica gel column chromatography via gradient elution with hexane/ethyl acetate mixtures.
Structure elucidation was facilitated by use of physical and spectroscopic methods, including high ﬁeld 2D NMR and mass spectroscopic techniques. The
crude extract as well asβ-sitosterol was seen to be selective inhibitors of the cyclooxygenase enzymeCOX-2. This work is of chemosystematic relevance as
it represents the ﬁrst isolation of β-sitostenone and stigmast-4-ene-3,6-dione from any species of Terminalia.
© 2012 SAAB. Published by Elsevier B.V. All rights reserved.
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to Africa, 11 of which occur over the southern African region
(Eloff et al., 2008). Of these, Terminalia sericea is best known for
its medicinal properties and is listed amongst the top 50 African
medicinal plants (Masoko and Eloff, 2005). The pharmacological
properties of several indigenous Terminalia species have been
established through antibacterial, antifungal, antiviral, anti-
inflammatory, anthelmintic and antioxidant assays (Eloff et al.,
2008; Masoko and Eloff, 2007; Masoko et al., 2005; Rabe and
Van Staden, 1997), whilst some of these species exhibited
activities against malarial, tuberculosis and schistosomiasis
pathogens (McGaw et al., 2008; Sibandze and Van Zyl, 2008;
Sparg et al., 2000). Of the South African complement, only T.
sericea has been examined phytochemically, leading to the
identification of anolignan B as the constituent antibacterial and
antifungal agent (Eldeen et al., 2006).Abbreviations: COX, cyclooxygenase; NMR, nuclear magnetic resonance.
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doi:10.1016/j.sajb.2012.06.001rightsThe ‘Lebombo cluster leaf’ Terminalia phanerophlebia Engl. &
Diels (also known as ‘amaNgwe ampofu’ in the Zulu vernacular)
ranges from eastern Cape province in South Africa, up to
Zimbabwe and east into Mozambique (Masoko et al., 2005).
Amongst the local tribal people it is used for a host of ailments,
including aches and pain, wounds and infections, gynaecological
conditions, inflammation, mental illness such as epilepsy, and
sexually-transmitted diseases (Stafford et al., 2008). Extracts of the
plant are also used for schistosomiasis and for treating patients
presenting with malaria-like symptoms (Sibandze and Van Zyl,
2008; Sparg et al., 2000). A recent survey of a series of South
African medicinal plants showed T. phanerophlebia to be amongst
the most efficacious against Candida albicans (MIC 0.02 mg/ml)
and Pseudomonas aeruginosa (MIC 0.16 mg/ml) which explained
the traditional use of the plant for such infections (Shai et al., 2008).
Based on the anti-inflammatory activity (92.4% inhibition of the
cyclooxygenase enzyme COX-2) initially observed for a crude
extract, stems of T. phanerophlebia were here examined
phytochemically, which revealed the known cholestanereserved.
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with the commercial anti-inflammatory agent β-sitosterol as
the active principles. The presence of β-sitostenone and stigmast-
4-ene-3,6-dione in T. phanerophlebia is significant since these
compounds have never been detected in the genus Terminalia,
which is known to contain over 100 species worldwide.
Plant material was collected during February 2011 at the
University of KwaZulu-Natal (Pietermaritzburg campus) and a
voucher specimen (JJN_02) was authenticated by Dr. Christina
Potgieter and deposited at the University Herbarium. The ethanol
extract of powdered dried stems was subjected to column
chromatography on silica gel by gradient elution with hexane/
ethyl acetate mixtures by which β-sitosterol, β-sitostenone and
stigmast-4-en-3,6-dione were isolated. Structure elucidation was
based on both physical and spectroscopic data which was in close
agreement with those from the literature (Li et al., 2008; Lim et al.,
2005; Prachayasittikul et al., 2009).
The anti-inflammatory activity of the crude extract was quite
pronounced, seen to effect up to 92.4% inhibition of the COX-2
enzyme (Table 1). This activity was modulated for COX-1, as
inhibition was only observed up to the 29.1% mark. The data in
Table 1 also confirmed the potency of β-sitosterol as an anti-
inflammatory agent (65.3% and 82.7% inhibition of COX-1 and
COX-2, respectively). At a similar concentration, β-sitostenone
was seen to elicit a much reduced response from both enzymes
with 15.3% and 4.1% inhibition of COX-1 and COX-2,
respectively. Interestingly, no interaction with COX-1 or COX-2
was observed for stigmast-4-ene-3,6-dione. Given the close
structural similarity of these compounds, we speculate that the
potency of β-sitosterol over the other two compounds may reside
in the formulation of the C-3,C-4,C-5,C-6 regions of themolecules,
and that extended conjugation throughα,β-unsaturation in the case
of β-sitostenone and stigmast-4-ene-3,6-dione may be deleterious
to enzyme inhibition. Both the crude extract and β-sitosterol were
seen to be selective in their interaction with the cyclooxygenase
enzymes, with COX-2 singled out for inhibition.Table 1
Cyclooxygenase (COX-1 and ‐2) activity of triterpenoid constituents of Terminalia
phanerophlebia.
Compound % Inhibition
COX-1 a COX-2 a
Crude ethanol extract b 29.1 (±1.57) 92.4 (±2.60)
β-Sitosterol c 65.3 (±1.30) 82.7 (±5.26)
β-Sitostenone d 15.3 (±2.50) 4.1 (±1.72)
Stigmast-4-ene-3,6-dione e na na
Indomethacin 78.8 (±3.18) f 60.1 (±3.46) g
Procedures are after Aremu et al. (2010).
a Values are means of three experiments, standard error is given in parentheses
(na = not active).
b Carried out at 250 μg/ml.
c Run at 483 μM.
d Run at 485 μM.
e Run at 497 μM.
f Carried out at 5 μM.
g Carried out at 200 μM.In terms of the phytochemical make-up of the genus
Terminalia, a diverse array of structures including lignans,
polyphenolics, saponins, tannins and triterpenoids of the choles-
tane, lupane, oleanane and ursane groups appear commonly across
members of the genus (Dwivedi, 2007). While β-sitosterol has
been reported from several species of Terminalia (Dwivedi, 2007),
the related cholestane triterpenoids β-sitostenone and stigmast-4-
ene-3,6-dione are novel to this genus. As such, their presence in T.
phanerophlebia is of chemosystematic relevance.
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